Welcome to our dedicated page for Iveric Bio news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on Iveric Bio stock.
Iveric Bio (NASDAQ: ISEE), now a subsidiary of Astellas Pharma, remains a leader in developing innovative therapies for retinal diseases including age-related macular degeneration. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic developments following the company's acquisition.
Access timely updates on Avacincaptad Pegol and other pipeline candidates targeting Geographic Atrophy. Our curated news collection features official press releases, trial result analyses, and partnership announcements from trusted sources. Track progress in ophthalmology research through verified updates on therapeutic advancements and regulatory pathways.
Key content includes updates on late-stage clinical programs, manufacturing developments, and scientific collaborations. All information is vetted for accuracy and relevance to investor decision-making. Bookmark this page for streamlined access to critical updates about Iveric Bio's contributions to retinal disease treatment under Astellas' global infrastructure.
Iveric Bio (NASDAQ: ISEE) announces participation in investor conferences in November 2022. Key events include the Credit Suisse 31st Annual Healthcare Conference on November 9 at 6:15 PM ET, Guggenheim's 4th Annual Neuro/Immunology Conference on November 14 at 2:45 PM ET, and the Stifel Healthcare Conference on November 15 at 11:30 AM ET. Live webcasts will be available on Iveric Bio's website, with archived replays accessible for 30 days. The company focuses on developing treatments for retinal diseases.
Iveric Bio (ISEE) announced the submission of the first part of its New Drug Application (NDA) to the FDA for avacincaptad pegol (ACP), a novel treatment for geographic atrophy due to age-related macular degeneration (AMD). This follows the completion of pivotal clinical trials, GATHER1 and GATHER2, both showing significant efficacy in slowing GA progression. The FDA has granted Fast Track designation for ACP, which underscores the drug’s potential to address unmet medical needs in this area.
IVERIC bio reported positive GATHER2 results for avacincaptad pegol (ACP) in treating geographic atrophy (GA), achieving its primary endpoint in two Phase 3 trials. The company plans to submit a New Drug Application (NDA) by year-end 2022, ahead of schedule, and is preparing for commercialization.
As of September 30, 2022, the company had $321 million in cash and expects to maintain sufficient liquidity through at least mid-2024. Q3 net loss was $42.4 million, or ($0.35) per share, vs. a $24.6 million loss in Q3 2021.
Iveric Bio (NASDAQ: ISEE) announced the granting of equity-based awards to eight new non-executive employees as part of its 2019 Inducement Stock Incentive Plan on November 1, 2022. The awards include non-statutory stock options for 122,800 shares with an exercise price of $23.95 and 15,500 restricted stock units. The stock options vest over four years, beginning November 1, 2023. Iveric Bio focuses on developing novel treatments for retinal diseases, aiming to enhance patients' quality of life.
Iveric Bio (NASDAQ: ISEE) will report its Q3 2022 financial results on November 3, 2022, at 8:00 a.m. ET. Following the results, management will host a live conference call and webcast for a comprehensive discussion of the financial outcomes and business updates. Investors can participate by calling 1-888-317-6003 (USA) or 1-412-317-6061 (International), with a passcode of 8170771. A replay will be available for two weeks post-call.
Iveric Bio, Inc. (NASDAQ: ISEE) announced on October 3, 2022, the granting of equity-based awards as part of its 2019 Inducement Stock Incentive Plan to two new non-executive employees. The inducement grants include non-statutory stock options to purchase 67,000 shares and 16,000 restricted stock units. The stock options have an exercise price of $18.26 per share and vest over four years. The plan aims to attract talent to support the company's focus on developing treatments for retinal diseases.
Iveric Bio (Nasdaq: ISEE) announced that top-line efficacy and safety results from its GATHER2 Phase 3 clinical trial of avacincaptad pegol (Zimura) will be presented at the American Academy of Ophthalmology 2022 annual meeting from September 30 to October 3 in Chicago. This marks the first public presentation of GATHER2 results, which demonstrated meeting the pre-specified primary endpoint of slowing geographic atrophy (GA) progression at 12 months. The company plans to submit a new drug application to the FDA by the end of Q1 2023.
Iveric Bio (NASDAQ: ISEE) announced its executives, Glenn P. Sblendorio and Pravin U. Dugel, M.D., will participate in two investor conferences this September. The Wells Fargo 2022 Healthcare Conference is scheduled for September 9 at 10:25 a.m. ET, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 at 2:50 p.m. ET. Investors can access live webcasts on the Iveric Bio website, with replays available for 30 days post-conference. Iveric Bio focuses on developing treatments for retinal diseases.
IVERIC bio announced positive topline results from the GATHER2 Phase 3 trial of Zimura, a complement C5 inhibitor for geographic atrophy (GA). GATHER2 met its primary endpoint with a 14.3% reduction in mean GA growth rate (p=0.0064) over 12 months. A significant 17.7% reduction was noted using observed GA area (p=0.0039). A New Drug Application (NDA) is planned for submission to the FDA by Q1 2023. The safety profile was favorable, with no significant ocular complications reported. These results follow GATHER1, solidifying Zimura's potential impact on treating GA.
Iveric Bio (NASDAQ: ISEE) announced on September 1, 2022, the granting of equity-based awards to two newly hired non-executive employees as part of its 2019 Inducement Stock Incentive Plan. This included 38,600 stock options priced at $9.89 per share and 8,000 restricted stock units. The stock options vest over four years, with partial vesting starting on September 1, 2023, while the restricted stock units will have staggered vesting dates in 2022 and 2023. These grants are intended as a material inducement for the employees to join the company.
